APRIOMED acquired by HALMA

Elos Medtech entered into an agreement to acquire 100% of Klingel Medical Group from IK Partners and its management team. The strategic rationale for the deal is to create a market-leading European MedTech CDMO with significantly enhanced R&D capabilities and a broader technological offering. The acquisition expands Elos Medtech's industrial presence in the DACH region by adding eight specialized manufacturing sites in Germany and Switzerland. Strategically, the combination aims to unlock cross-selling opportunities and provides Klingel with increased visibility and distribution channels in the U.S. market. This milestone consolidation allows the combined entity to leverage a global footprint to drive operational improvements and cater to the unique needs of international OEM customers in the medical device sector.

Novo Nordisk, the global leader in insulin production, has announced the acquisition of Biocorp, a French medtech company specialized in connected drug delivery devices. The transaction began with the acquisition of the 45.3% stake held by the main shareholder, Bio Jag, followed by a mandatory simplified tender offer for the remaining shares.

Sartorius Stedim Biotech has reached a definitive agreement to acquire one hundred percent of the share capital of Polyplus from private equity sponsors ArchiMed and Warburg Pincus. This landmark transaction is structured as a full buyout, effectively transferring ownership from financial sponsors to a strategic corporate acquirer. The operation is financially underpinned by a bridge loan facility secured by the acquirer's parent company through J.P. Morgan, which is expected to be ultimately refinanced via long-term financial instruments potentially incorporating an equity component. This platform investment represents a highly synergistic and value-accretive maneuver for the acquirer, structurally designed to capture a significant share of the rapidly expanding cell and gene therapy market. The acquisition introduces vital technological complementarities, specifically bridging the target's pioneering expertise in viral vector production components with the acquirer’s established portfolio of cell culture media and advanced therapy essentials. By internalizing these capabilities, the acquirer strengthens its footprint in the United States while capitalizing on a sector characterized by high structural growth and accelerating pipeline developments. The financial parameters of the transaction underscore the premium nature of the target asset, driven by an intensively competitive environment wherein proactive industrial consolidators rapidly outpaced financial sponsors during the preemptive phase of the process. The deal delivers an exceptional exit profile for the incumbent sponsors, culminating in an impressive multiple on invested capital realized over the investment holding period.

Ardian took a majority stake in Theradial alongside historical shareholder UI Investissement. Bpifrance and the management team remain minority shareholders. The transaction, valuing the company between EUR100M and EUR200M, aims to accelerate international expansion and support a buy-and-build strategy, particularly in data-driven healthcare solutions.

Stanley Capital Partners acquired a majority stake in Laboratoire X.O following the liquidation of its former owner, Novalpina Capital. The deal resolved a year-long legal dispute between management and transitional managers (BRG). This new phase focuses on a strategic merger with Noden Pharma (another SCP portfolio company), providing X.O with a commercial platform in Ireland and the United States. The goal remains to triple revenue within 3-4 years through aggressive portfolio acquisitions.

Unither Pharmaceuticals, a global leader in sterile single-unit dosage manufacturing, has undergone a capital reorganization led by its management team and a consortium of prominent investors. GIC and IK Partners have entered as new equity partners, while Keensight Capital and Parquest are reinvesting to reinforce their existing positions. The consortium is acquiring the majority stake from Ardian, following a successful five-year partnership.

Catalent has executed a definitive binding agreement to acquire Metrics Contract Services, a specialized CDMO subsidiary, from Australia-based Mayne Pharma Group. Concurrently with the main transaction, the parties established a five-year commercial supply agreement alongside a transition service agreement (TSA), ensuring a seamless operational integration and absolute supply continuity for the divesting parent’s retained product portfolio. This transaction represents a highly value-accretive platform investment purposefully designed to expand integrated global oral solid formulation capabilities. The core industrial logic centers on securing immediate, fit-for-scale capacity in the specialized potent handling space. With biopharma R&D pipelines increasingly pivoting towards complex oncology and rare disease programs, securing advanced potent compound manufacturing capabilities efficiently mitigates supply chain shortfalls. Furthermore, the seamless integration of a state-of-the-art facility significantly accelerates an ongoing capacity expansion blitz, allowing the acquirer to rapidly meet escalating client demand without the extensive lead times typically associated with greenfield development. This operation sends a definitive signal of continued sector consolidation within the high-value CDMO landscape. It highlights a robust appetite among tier-one industry players to deploy dry powder for premium niche capabilities, particularly within the high-barrier-to-entry potent drug handling segment. This move establishes a rigorous benchmark for asset valuations within the oral solid dose niche, reaffirming that state-of-the-art infrastructure catering to high-growth therapeutic areas continues to command exceptional strategic interest.

Healthcare-focused investment firm Mérieux Equity Partners has completed the strategic merger of two of its existing portfolio companies, Addmedica and Laboratoires CTRS, creating a new consolidated entity named Theravia Pharma. As part of this corporate combination, the sponsor—which already held existing stakes in both businesses—elected to significantly increase its overall equity position. Mérieux EP rolled over its historical shares and convertible bonds while simultaneously acquiring additional equity, notably buying out the exiting founders of Addmedica. This move enabled the fund to step up its ownership and secure a majority controlling stake of approximately 70% in the newly formed group. The equity enhancement and the refinancing of existing credit facilities were supported by the successful raising of new senior debt.

TPG Capital has signed a binding agreement to acquire a majority stake in DOC Generici from ICG and Mérieux Equity Partners. The strategic rationale for the transaction is driven by the continued expansion of the Italian generic drug market and DOC Generici's position as a reference brand for patients and healthcare providers. TPG intends to partner with the existing management team to accelerate the company’s leadership through significant investment in organic growth and external consolidation. This acquisition represents a continuation of the company's successful history as a private equity-backed consolidation platform, following previous ownership cycles under Charterhouse, CVC, and ICG. The entry of TPG is expected to provide the capital and global infrastructure necessary to further diversify the product portfolio and optimize the supply chain, ensuring the long-term delivery of high-quality, low-cost medication within the European regulatory framework.

A consortium of prominent financial sponsors, led by UI Investissement and supported by GENEO Capital Entrepreneur alongside historical partner Crédit Agricole Centre France, has successfully executed a growth equity investment in Neftys Pharma. The transaction is structured around a €30 million capital increase, injected directly into the company's balance sheet to fuel its ambitious expansion trajectory. Concurrently, the financial sponsors' equity injection is optimally paired with a newly secured, structured debt financing package exceeding €52 million, provided by the firm's historical banking syndicate. This platform investment is fundamentally rooted in a robust value-creation thesis aimed at accelerating the company's aggressive buy-and-build strategy across the fragmented European animal health market. By infusing significant dry powder into the business, the financial consortium provides Neftys Pharma with the requisite firepower to execute highly accretive external growth opportunities, aiming to double its size over the next five years.